Trials of new anti-diabetes agents. - Wikidata - wikimedia - TriplyDB

Trials of new anti-diabetes agents.

Trials of new anti-diabetes agents.

http://www.wikidata.org/entity/Q53573529

about

Trials of new anti-diabetes agents.

http://www.wikidata.org/entity/Q53573529

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Trials of new anti-diabetes agents.

@en

Trials of new anti-diabetes agents.

@nl

type

label

Trials of new anti-diabetes agents.

@en

Trials of new anti-diabetes agents.

@nl

prefLabel

Trials of new anti-diabetes agents.

@en

Trials of new anti-diabetes agents.

@nl

P1433

Q53573529-87DB6F67-8544-4EE9-94B5-F0B92FC38BC5

P1476

Q53573529-DF670955-7368-4E22-8923-5E40476B766A

P2093

Q53573529-D05FCED2-4C33-4227-BC7A-C5873140B4A4

P2860

Q53573529-0C33C8E2-4B0E-4137-8CF0-79B7AF3459A4

Q53573529-14E45940-63B8-45DF-AE39-317A8F13044F

Q53573529-40DDFFBA-B221-4B9D-82C0-0BDF6B9898F5

Q53573529-7BE2E1F0-DE88-485A-9C18-F13160CFB2F0

Q53573529-8283F218-7968-45E2-9C30-251A9748F6C7

Q53573529-9AA236F2-5F58-4EC8-9313-73F161375D96

Q53573529-B0553DE7-57E6-4BFD-BCF5-0499DB8B683F

Q53573529-EEBE287F-C4B1-4FDA-9075-6427CAB10426

P304

Q53573529-1290E881-52AB-4502-AEA0-B14EED56B99F

P31

Q53573529-79B00A13-E8CC-44BC-82A0-FD6DD2BF6251

Q53573529-f7c82d43-eb4f-4a63-b809-60fc4ce88296

P356

Q53573529-1CBC816E-E954-4DD3-9E14-320D71908994

P433

Q53573529-FA2DBC9F-6B7D-434C-90A8-B7968A8290E8

P478

Q53573529-9BE0AFF6-273B-4487-A900-68904E2BCA08

P577

Q53573529-69359E18-1614-4F4A-9A45-27F71B3222B2

P698

Q53573529-B16D56B2-FBE3-419C-979E-D6EF3CF77957

P356

P1433

Diabetic Medicine

P1476

Trials of new anti-diabetes agents.

@en

P2093

R I G Holt

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.

Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST® : SIMPLE USE).

Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study.

Psychological outcomes of evening and night closed-loop insulin delivery under free living conditions in people with Type 1 diabetes: a 2-month randomized crossover trial.

RD Lawrence Lecture 2015 Old habits are hard to break: lessons from the study of hypoglycaemia.

Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.

Sitagliptin plus pantoprazole can restore but not maintain insulin independence after clinical islet transplantation: results of a pilot study.

P304

147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DME.13306

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28090726

http://www.w3.org/2001/XMLSchema#string